Supreme Court stays 5th Circuit mifepristone in-person dispensing rule to 11 May 2026
Telehealth prescribers and mail-order pharmacy compliance teams handling mifepristone retain telemedicine and mail dispensing only until the administrative stay expires on 11 May 2026
- — Telehealth clinic operators and mail-order pharmacy compliance teams must scope mifepristone prescribing and dispensing without in-person visit to within the 11 May 2026 stay window — post-expiry operations become unlawful if the 5th Circuit rule reattaches.
- — Mifepristone manufacturers' legal teams (Danco Laboratories; GenBioPro) must prosecute emergency relief on the Supreme Court's briefing schedule — Louisiana's response deadline (Thursday) and stay expiry (11 May 2026) control whether current dispensing rules remain operative.
- — Telehealth clinic operators prescribing mifepristone
- — Mail-order pharmacy compliance teams dispensing mifepristone
- — Mifepristone manufacturers' legal teams (Danco Laboratories; GenBioPro)
- — Louisiana response due Thursday — required before Supreme Court acts on emergency requests
- — 11 May 2026 — stay expires; 5th Circuit in-person rule may reattach without further Supreme Court ruling